Company Overview
Snapshot
Founded in January 2020 by Dean Bitan, Shahar Porat, and Jonathan Zalach, Imagene operates with 11–50 employees. The company has raised $44.5M across 3 funding rounds from 6 investors. In July 2025, Imagene secured Series B funding, with Larry Ellison participating.
Business overview
Imagene leverages AI to profile a broad range of biomarkers from biopsy images in real-time, aiming to democratize precision medicine for cancer patients. The company's technology classifies patterns invisible to the human eye, integrating genomics, proteomics, and spatial insights for rapid and accurate molecular profiling. Imagene serves the healthcare and life sciences sectors, including pharmaceutical companies, hospitals, and healthcare providers, by enabling better patient stratification for clinical trials and the discovery of novel drug targets. Its core products include the Oncology Intelligence Foundation Model, LungOI, and CanvOI, operating within the Digital Healthcare and Digital Medical Diagnostics categories.
Strategic signal
In September 2024, Imagene launched its CanvOI model, powered by Oracle Cloud, to advance cancer treatment. This initiative signals a strategic collaboration with a major technology provider to scale its AI capabilities and accelerate the development of its oncology intelligence platform, indicating a strong focus on leveraging cloud infrastructure for broader market reach and enhanced diagnostic precision.
Log in to access full profile ›Company Intelligence Q&A
- What is Imagene's core mission?
- Imagene's mission is to leverage AI for real-time biomarker profiling from biopsy images, overcoming economic, logistical, and technological barriers to make precision medicine accessible to all cancer patients.
- When did Imagene launch its CanvOI model?
- In September 2024, Imagene launched its CanvOI model, powered by Oracle Cloud, to advance cancer treatment.
- What was a significant recognition Imagene received in 2023?
- In October 2023, Imagene won the 2023 Digital Health Awards for "Best use of AI in Health Tech" from the Digital Health Hub Foundation.
- What was a key product announcement from Imagene in September 2023?
- In September 2023, Imagene announced LungOI, the first AI-based NSCLC molecular panel designed for immediate cancer biomarker profiling.
- Which investor participated in Imagene's Series B funding round?
- In July 2025, Imagene raised $23M in Series B funding. Larry Ellison led the round, with participation from Aguras.